August 6, 2026 · Decision research
Biotech Pharma Breakthroughs
Finding
The weakest assumption is that oral delivery automatically converts GLP-1 efficacy into durable, superior economics. Current evidence supports oral adoption, but not that economic conclusion: pills are gaining users while efficacy gaps, gastrointestinal discontinuation, and net-price pressure remain material.
What changed
Current primary-source evidence now shows both sides of the test. Orforglipron has an FDA label with initial U.S. approval in 2026, and Novo reports more than 5 million cumulative Wegovy pill prescriptions by week 30. At the same time, Q2 2026 results show strong volume but falling realized prices at both leading manufacturers.
Decision
Do not change the action to an outright reject, but do change its scope: retain CONSIDER only for commercially validated leaders and evidence-backed catalysts. Do not upgrade to a broad GLP-1 buy or treat the oral category as proven economics until persistence and net price are demonstrated.
Watch next
The next decision hinge is whether oral users persist at scale while price declines stabilize. Upgrade only if volume growth persists with improving or stable realized price and real-world persistence; downgrade if volume requires accelerating discounts or if oral discontinuation remains high outside selected trial populations.